Shares in Orthocell jumped after the medtech gained approval to sell its dental bone and soft tissue regeneration solution in Europe.
The company came out of a trading halt and the shares took off. A short time ago, they were 16% higher at $0.36.
The Perth-based regenerative medicine company announced European regulatory approval for its CelGro collagen medical device.
“This provides a strong foundation for Orthocell to progress additional dental regulatory applications in key markets, such as the US, Japan and Australia,” says Orthocell Managing Director Paul Anderson.